CASI Pharmaceuticals, Inc. (CASIF)
OTCMKTS · Delayed Price · Currency is USD
0.1288
+0.0088 (7.33%)
At close: Aug 11, 2026
CASI Pharmaceuticals Revenue
In the year 2025, CASI Pharmaceuticals had annual revenue of $20.71M, down -27.42%. CASI Pharmaceuticals had revenue of $7.22M in the quarter ending December 31, 2025, a decrease of -45.93%.
Revenue
20.71M
Revenue Growth
-27.42%
P/S Ratio
0.13
Revenue / Employee
96.79K
Employees
214
Market Cap
2.65M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 20.71M | -7.83M | -27.42% |
| Dec 31, 2024 | 28.54M | -5.34M | -15.77% |
| Dec 31, 2023 | 33.88M | -9.23M | -21.41% |
| Dec 31, 2022 | 43.11M | 12.94M | 42.89% |
| Dec 31, 2021 | 30.17M | 15.03M | 99.25% |
| Dec 31, 2020 | 15.14M | 11.01M | 266.52% |
| Dec 31, 2019 | 4.13M | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | 47.71K | 23.99K | 101.09% |
| Dec 31, 2014 | 23.73K | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | 669.31K | -1.27M | -65.52% |
| Dec 31, 2011 | 1.94M | -1.75M | -47.45% |
| Dec 31, 2010 | 3.69M | -1.59M | -30.11% |
| Dec 31, 2009 | 5.28M | -2.19M | -29.33% |
| Dec 31, 2008 | 7.48M | 81.57K | 1.10% |
| Dec 31, 2007 | 7.40M | 501.29K | 7.27% |
| Dec 31, 2006 | 6.89M | 976.30K | 16.50% |
| Dec 31, 2005 | 5.92M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| International Stem Cell | 9.29M |
| Pacific Software | 2.40M |
| Orgenesis | 1.04M |
| Vaccinex | 601.00K |
| Eastgate Biotech | 137.64K |
| Enzolytics | 46.59K |
| VitaSpring Biomedical | -1.49M |
CASI Pharmaceuticals News
- 5 months ago - CASI Pharmaceuticals Receives the Delisting Decision From the Nasdaq Hearings Panel - Accesswire
- 7 months ago - CASI Pharmaceuticals Announces Approval of Clinical Trial Application by China NMPA for Phase 1 / 2 Study of CID-103 for Renal Allograft Antibody-Mediated Rejection (AMR) - Accesswire
- 7 months ago - CASI Pharmaceuticals Announces Update and Additional Results from Phase 1 Study of CID-103 in Adult Patients with Chronic Immune Thrombocytopenia - Accesswire
- 8 months ago - CASI Pharmaceuticals Receives Extension from Nasdaq to Meet Listing Requirements - Accesswire
- 8 months ago - CASI Pharmaceuticals Announces Up to $20 Million Convertible Note Financing - Accesswire
- 8 months ago - CASI Pharmaceuticals Announces Results from CID-103 Immune Thrombocytopenia Study at the 67th American Society of Hematology (ASH) Annual Meeting - Accesswire
- 9 months ago - CASI Pharmaceuticals Announces Changes in Board Governance - Accesswire
- 9 months ago - CASI Pharmaceuticals Announces Third Quarter 2025 Business and Financial Results - Accesswire